ECM Weekly (30th May 2021) - JD Log, Monde Nissin, Weilong Deli, Kanzhun, CARsgen, WM Tech, Novotech
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.
296 Views
CARSgen Therapeutics IPO: Catalyzing Cancer Therapies
CARSgen’s core product CT053 shows significant potential given its positive ORR and receiving the US FDA RMAT designation.
382 Views
CARsgen Therapeutics IPO Initiation: Choosing Therapies À La CAR-T
CARsgen is pre-marketing an HKEx IPO to raise proceeds of $400-500m. The promising prospects for the lead product, credible management and a good...
324 Views
CARsgen (科济药业) Pre-IPO: Thoughts on Valuation
In this insight, we provide a risk-adjusted NPV based valuation for the company's key product CT035 and the SOTP valuation for the company.
363 Views
Pre-IPO Keymed Biosciences - Challenges Are Inevitable Despite Some Advantages on Pipeline
This article analyzed Keymed Biosciences in terms of the insights on core product CM310 and two key products CM326 and CMG901, the advantages, the...
718 Views